CCTG MA.39:Tailor RT: A Randomized Trial of Regional Radiotherapy in Biomarker Low Risk Node Positive and T3N0 Breast Cancer
Objective
Primary Objective: To compare the breast cancer recurrence-free interval (BCRFI) between patients that received regional RT or not, defined as time from randomization to time of invasive recurrent disease in the ipsilateral chestwall, breast, regional nodes, distant sites or death due to BC.
Secondary Objectives: To compare the invasive disease-free survival (DFS) between patients that received regional RT or not. To compare the breast cancer mortality between patients that received regional RT or not. To compare the overall survival (OS) between patients that received regional RT or not. To compare the locoregional recurrence-free interval (LRRFI) between patients that received regional RT or not. To compare the distant recurrence-free interval (DRFI) between patients that received regional RT or not. To compare the toxicity between patients that received regional RT or not. To compare arm volume and mobility measurements between patients that received regional RT or not. To compare patient reported outcomes (PROs) and the quality of life (QOL) between patients that received regional RT or not (enrollment completed 2022AUG02). To compare the cost effectiveness between patients that received regional RT or not (enrollment completed 2022AUG02).
